2-amino-N&#39;-benzylideneacetohydrazides and Derivatives for the Management of CFTR Protein Mediated Diseases

ABSTRACT

This disclosure relates to methods of treating or preventing cystic fibrosis transmembrane conductance regulator (CFTR) mediated diseases such as cystic fibrosis, chronic obstructive pulmonary disease, chronic pancreatitis, chronic bronchitis, asthma, mucus formation, comprising administering an effective amount of a 2-amino-N′-benzylidene-acetohydrazide compound or derivative thereof to a subject in need thereof. In certain embodiments, the 2-amino-N′-benzylidene-acetohydrazide compound is ((E)-N′-(3,5-dibromo-2,4-dihydroxybenzylidene)-2-(m-tolylamino)acetohydrazide; or (E)-N′-(3,5-dibromo-2,4-dihydroxybenzylidene)-2-(p-tolylamino)acetohydrazide.

CROSS-REFERENCE TO RELATED APPLICATIONS

This application is a division of U.S. patent application Ser. No.15/578,100 filed Nov. 29, 2017, which is the National Stage ofInternational Application No. PCT/US2016/034662 filed May 27, 2016,which claims the benefit of U.S. Provisional Application No. 62/168,022filed May 29, 2015. The entirety of each of these applications is herebyincorporated by reference for all purposes.

INCORPORATION-BY-REFERENCE OF MATERIAL SUBMITTED AS A TEXT FILE VIA THEOFFICE ELECTRONIC FILING SYSTEM (EFS-WEB)

The Sequence Listing associated with this application is provided intext format in lieu of a paper copy and is hereby incorporated byreference into the specification. The name of the text file containingthe Sequence Listing is 15086USDIV_ST25.txt. The text file is 14 KB, wascreated on Jan. 2, 2020, and is being submitted electronically viaEFS-Web.

BACKGROUND

Cystic fibrosis (CF) is a lethal, recessive, genetic disease caused bymutations in the cystic fibrosis transmembrane conductance regulator(CFTR) protein. The cystic fibrosis CFTR protein functions as a cellsurface ion channel. Mutations of CFTR are thought to reduce cellsurface expression and/or the ion transport function. This causesdecreased water secretion by cells and ultimately thicker mucus layerslining the membranes in the lungs and other parts of the body. Inaddition to cystic fibrosis, certain CFTR mutations cause recurrentacute and chronic pancreatitis. As an inherited disease, there is nocure for cystic fibrosis; thus, there is a need to identify improvedtherapies.

Ivacaftor is indicated for the treatment of cystic fibrosis and acts asa potentiator of CFTR by enhancing ion channel transport. Ivacaftor isalso approved for treatment in combination with lumacaftor for patientswho have a deletion of the codon for phenylalanine (F) at position 508,referred to as the F508-del mutation. Having the F508-del mutationreduces escape of CFTR from the endoplasmic reticulum. Lumacaftor isreported to increase the trafficking of CFTR to the cell surface. Thecombination of Ivacaftor and lumacaftor is also approved for patientswith other CFTR mutations.

The activities of CFTR channels were also identified to be modulated byseveral other compounds. Potentiators include P1 (VRT-532), P2 (PG-01),and P3 (SF-03). See Caldwell et al., Increased folding and channelactivity of a rare cystic fibrosis mutant with CFTR modulators, Am JPhysiol Lung Cell Mol Physiol, 2011, 301(3):L346-52. Other CFTR alteringcompounds include GlyH-101, NPPB, and glibenclamide. See Cui et al.,Murine and human CFTR exhibit different sensitivities to CFTRpotentiators, Am J Physiol Lung Cell Mol Physiol, 2015, 309(7):L687-99.

-   Dransfield et al. report acquired CFTR dysfunction in the lower    airways in chronic obstructive pulmonary disease (COPD). Chest.    2013, 144(2):498-506. Raju et al. report acquired CFTR dysfunction    in chronic bronchitis and other conditions of mucus clearance. Clin    Chest Med, 2016, 37 147-158.-   Yang et al. report that molecules that inhibit CFTR slow cyst growth    in polycystic kidney disease. J Am Soc Nephrol, 2008, 19(7):    1300-1310.-   Thiagarajah & Verkman report CFTR inhibitors for treating diarrheal    disease. Clin Pharmacol Ther, 2012, 92(3):287-90.

References cited herein are not an admission of prior art.

BRIEF DESCRIPTION OF THE SEVERAL VIEWS OF THE DRAWING(S)

FIG. 1 illustrates the structure of GlyH-101, OSSK-2, and OSSK-3.

FIG. 2A shows data on the effect of OSSK-3 on wildtype human (hCFTR) at20 uM. Dashed lines show the maximum plateau current before chemicals.

FIG. 2B shows data on the effect of OSSK-3 on hCFTR at 5 uM.

FIG. 2C shows data on the effect of OSSK-2 on hCFTR at 5 uM.

FIG. 3A shows data on OSSK-3 potentiated F508 del-hCFTR compared to WT.

FIG. 3B shows data on OSSK-2 potentiated F508 del-hCFTR compared to WT.

FIG. 4A shows data on the effect of OSSK-3 on F508 del-hCFTR at 5 uM.

FIG. 4B shows data on the effect of OSSK-2 on F508 del-hCFTR at 5 uM.

FIG. 4C shows data on the effect of ivacaftor (VX-770) on F508 del-hCFTRat 5 uM.

SUMMARY

This disclosure relates to methods of treating or preventing cysticfibrosis transmembrane conductance regulator (CFTR) mediated diseasessuch as cystic fibrosis, chronic obstructive pulmonary disease, chronicpancreatitis, chronic bronchitis, asthma, the formation of mucus, orconditions associated therewith comprising administering an effectiveamount of a 2-amino-N′-benzylidene-acetohydrazide compound, salt, orderivative thereof to a subject in need thereof.

In certain embodiments, the 2-amino-N′-benzylideneacetohydrazidecompound, salt, or derivative is selected from:(E)-N′-(3,5-dibromo-2,4-dihydroxybenzylidene)-2-(m-tolylamino)acetohydrazide;and(E)-N′-(3,5-dibromo-2,4-dihydroxybenzylidene)-2-(p-tolylamino)acetohydrazide.

In certain embodiments, the disclosure relates to methods of treating orpreventing pancreatic dysfunction, such as recurrent, acute, or chronicpancreatitis, comprising administering an effective amount of a2-amino-N′-benzylideneacetohydrazide compound, salt, or derivativethereof to a subject in need thereof.

In certain embodiments, the subject is exhibiting symptoms or, at riskof, or diagnosed with cystic fibrosis, chronic obstructive pulmonarydisease, chronic bronchitis, asthma, recurrent, acute, or chronicpancreatitis.

In certain embodiments, the 2-amino-N′-benzylideneacetohydrazidecompound, salt, or derivative is administered in combination withanother therapeutic agent, such as lumacaftor or other compound thatpotentiates CFTR and/or increases cell surface expression. In certainembodiments, the 2-amino-N′-benzylideneacetohydrazide compound, salt, orderivative is administered in combination with pancreatic enzymesupplements, anti-bacterial agents, anti-viral agents, anti-inflammatoryagents, mucus reducing agents, and/or gene therapies.

In certain embodiments, the disclosure relates to pharmaceuticalcomposition comprising a compound disclosed herein and apharmaceutically acceptable excipient. In certain embodiments, thepharmaceutical composition is in the form of a pill, tablet, capsule,aerosol, or an aqueous buffer solution, typically a saline phosphatebuffer between a pH of 6 to 8, optionally comprising a saccharide orpolysaccharide.

DETAILED DESCRIPTION

Before the present disclosure is described in greater detail, it is tobe understood that this disclosure is not limited to particularembodiments described, and as such may, of course, vary. It is also tobe understood that the terminology used herein is for the purpose ofdescribing particular embodiments only, and is not intended to belimiting, since the scope of the present disclosure will be limited onlyby the appended claims.

Unless defined otherwise, all technical and scientific terms used hereinhave the same meaning as commonly understood by one of ordinary skill inthe art to which this disclosure belongs. Although any methods andmaterials similar or equivalent to those described herein can also beused in the practice or testing of the present disclosure, the preferredmethods and materials are now described.

All publications and patents cited in this specification are hereinincorporated by reference as if each individual publication or patentwere specifically and individually indicated to be incorporated byreference and are incorporated herein by reference to disclose anddescribe the methods and/or materials in connection with which thepublications are cited. The citation of any publication is for itsdisclosure prior to the filing date and should not be construed as anadmission that the present disclosure is not entitled to antedate suchpublication by virtue of prior disclosure. Further, the dates ofpublication provided could be different from the actual publicationdates that may need to be independently confirmed.

As will be apparent to those of skill in the art upon reading thisdisclosure, each of the individual embodiments described and illustratedherein has discrete components and features which may be readilyseparated from or combined with the features of any of the other severalembodiments without departing from the scope or spirit of the presentdisclosure. Any recited method can be carried out in the order of eventsrecited or in any other order that is logically possible.

Embodiments of the present disclosure will employ, unless otherwiseindicated, techniques of medicine, organic chemistry, biochemistry,molecular biology, pharmacology, molecular modeling, and the like, whichare within the skill of the art. Such techniques are explained fully inthe literature.

It must be noted that, as used in the specification and the appendedclaims, the singular forms “a,” “an,” and “the” include plural referentsunless the context clearly dictates otherwise. In this specification andin the claims that follow, reference will be made to a number of termsthat shall be defined to have the following meanings unless a contraryintention is apparent.

Certain of the compounds described herein may contain one or moreasymmetric centers and may give rise to enantiomers, diastereomers, andother stereoisomeric forms that can be defined, in terms of absolutestereochemistry at each asymmetric atom, as (R)- or (S)-. The presentchemical entities, pharmaceutical compositions and methods are meant toinclude all such possible isomers, including racemic mixtures, tautomerforms, hydrated forms, optically substantially pure forms andintermediate mixtures.

Unless otherwise stated, structures depicted herein are also meant toinclude compounds which differ only in the presence of one or moreisotopically enriched atoms. For example, compounds having the presentstructures except for the replacement or enrichment of a hydrogen bydeuterium or tritium at one or more atoms in the molecule, or thereplacement or enrichment of a carbon by ¹³C or ¹⁴C at one or more atomsin the molecule, are within the scope of this disclosure. In oneembodiment, provided herein are isotopically labeled compounds havingone or more hydrogen atoms replaced by or enriched by deuterium. In oneembodiment, provided herein are isotopically labeled compounds havingone or more hydrogen atoms replaced by or enriched by tritium. In oneembodiment, provided herein are isotopically labeled compounds havingone or more carbon atoms replaced or enriched by ¹³C. In one embodiment,provided herein are isotopically labeled compounds having one or morecarbon atoms replaced or enriched by ¹⁴C.

As used herein, “alkyl” means a noncyclic straight chain or branched,unsaturated or saturated hydrocarbon such as those containing from 1 to22 carbon atoms, while the term “lower alkyl” or “C₁₋₄alkyl” has thesame meaning as alkyl but contains from 1 to 4 carbon atoms. The term“higher alkyl” has the same meaning as alkyl but contains from 8 to 22carbon atoms. Representative saturated straight chain alkyls includemethyl, ethyl, n-propyl, n-butyl, n-pentyl, n-hexyl, n-septyl, n-octyl,n-nonyl, and the like; while saturated branched alkyls includeisopropyl, sec-butyl, isobutyl, tert-butyl, isopentyl, and the like.Unsaturated alkyls contain at least one double or triple bond betweenadjacent carbon atoms (referred to as an “alkenyl” or “alkynyl”,respectively). Representative straight chain and branched alkenylsinclude ethylenyl, propylenyl, 1-butenyl, 2-butenyl, isobutylenyl,1-pentenyl, 2-pentenyl, 3-methyl-1-butenyl, 2-methyl-2-butenyl,2,3-dimethyl-2-butenyl, and the like; while representative straightchain and branched alkynyls include acetylenyl, propynyl, 1-butynyl,2-butynyl, 1-pentynyl, 2-pentynyl, 3-methyl-1-butynyl, and the like.

Non-aromatic mono or polycyclic alkyls are referred to herein as“carbocycles” or “carbocyclyl” groups. Representative saturatedcarbocycles include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl,and the like; while unsaturated carbocycles include cyclopentenyl andcyclohexenyl, and the like.

“Heterocarbocycles” or heterocarbocyclyl” groups are carbocycles whichcontain from 1 to 4 heteroatoms independently selected from nitrogen,oxygen and sulfur which may be saturated or unsaturated (but notaromatic), monocyclic or polycyclic, and wherein the nitrogen and sulfurheteroatoms may be optionally oxidized, and the nitrogen heteroatom maybe optionally quaternized. Heterocarbocycles include morpholinyl,pyrrolidinonyl, pyrrolidinyl, piperidinyl, hydantoinyl, valerolactamyl,oxiranyl, oxetanyl, tetrahydrofuranyl, tetrahydropyranyl,tetrahydropyridinyl, tetrahydroprimidinyl, tetrahydrothiophenyl,tetrahydrothiopyranyl, tetrahydropyrimidinyl, tetrahydrothiophenyl,tetrahydrothiopyranyl, and the like.

“Aryl” means an aromatic carbocyclic monocyclic or polycyclic ring suchas phenyl or naphthyl. Polycyclic ring systems may, but are not requiredto, contain one or more non-aromatic rings, as long as one of the ringsis aromatic. “Arylalkyl” means an alkyl substituted with an aryl, e.g.,benzyl, methyl substituted with phenyl.

As used herein, “heteroaryl” refers to an aromatic heterocarbocyclehaving 1 to 4 heteroatoms selected from nitrogen, oxygen and sulfur, andcontaining at least 1 carbon atom, including both mono- and polycyclicring systems. Polycyclic ring systems may, but are not required to,contain one or more non-aromatic rings, as long as one of the rings isaromatic. Representative heteroaryls are furyl, benzofuranyl,thiophenyl, benzothiophenyl, pyrrolyl, indolyl, isoindolyl, azaindolyl,pyridyl, quinolinyl, isoquinolinyl, oxazolyl, isooxazolyl, benzoxazolyl,pyrazolyl, imidazolyl, benzimidazolyl, thiazolyl, benzothiazolyl,isothiazolyl, pyridazinyl, pyrimidinyl, pyrazinyl, triazinyl,cinnolinyl, phthalazinyl, and quinazolinyl. It is contemplated that theuse of the term “heteroaryl” includes N-alkylated derivatives such as a1-methylimidazol-5-yl substituent.

As used herein, “heterocycle” or “heterocyclyl” refers to mono- andpolycyclic ring systems having 1 to 4 heteroatoms selected fromnitrogen, oxygen and sulfur, and containing at least 1 carbon atom. Themono- and polycyclic ring systems may be aromatic, non-aromatic ormixtures of aromatic and non-aromatic rings. Heterocycle includesheterocarbocycles, heteroaryls, and the like.

“Alkylthio” refers to an alkyl group as defined above attached through asulfur bridge. An example of an alkylthio is methylthio, (i.e., —S—CH₃).

“Alkoxy” refers to an alkyl group as defined above attached through anoxygen bridge. Examples of alkoxy include, but are not limited to,methoxy, ethoxy, n-propoxy, i-propoxy, n-butoxy, s-butoxy, t-butoxy,n-pentoxy, and s-pentoxy. Preferred alkoxy groups are methoxy, ethoxy,n-propoxy, i-propoxy, n-butoxy, s-butoxy, and t-butoxy.

“Alkylamino” refers to an alkyl group as defined above attached throughan amino bridge.

An example of an alkylamino is methylamino, (i.e., —NH—CH₃).

“Alkanoyl” refers to an alkyl as defined above attached through acarbonyl bride (i.e., —(C═O)alkyl).

“Alkylsulfonyl” refers to an alkyl as defined above attached through asulfonyl bridge (i.e., —S(═O)₂alkyl) such as mesyl and the like, and“Arylsulfonyl” refers to an aryl attached through a sulfonyl bridge(i.e., —S(═O)₂aryl).

“Alkylsulfinyl” refers to an alkyl as defined above attached through asulfinyl bridge (i.e. —S(═O)alkyl).

“Aminoalkyl” refers to an amino group attached through an alkyl bridge.An example of an aminoalkyl is aminomethyl, (i.e., NH₂—CH₂—).

“Hydroxyalkyl” refers to a hydroxy group attached through an alkylbridge. An example of a hydroxyalkyl is hydroxyethyl, (i.e.,HO—CH₂CH₂—).

The term “substituted” refers to a molecule wherein at least onehydrogen atom is replaced with a substituent. When substituted, one ormore of the groups are “substituents.” The molecule may be multiplysubstituted. In the case of an oxo substituent (“═O”), two hydrogenatoms are replaced. Example substituents within this context may includehalogen, hydroxy, alkyl, alkoxy, nitro, cyano, oxo, carbocyclyl,carbocycloalkyl, heterocarbocyclyl, heterocarbocycloalkyl, aryl,arylalkyl, heteroaryl, heteroarylalkyl, —NRaRb, —NRaC(═O)Rb,—NRaC(═O)NRaNRb, —NRaC(═O)ORb, —NRaSO2Rb, —C(═O)Ra, —C(═O)ORa,—C(═O)NRaRb, —OC(═O)NRaRb, —ORa, —SRa, —SORa, —S(═O)₂Ra, —OS(═O)₂Ra and—S(═O)₂ORa. Ra and Rb in this context may be the same or different andindependently hydrogen, halogen hydroxyl, alkyl, alkoxy, alkyl, amino,alkylamino, dialkylamino, carbocyclyl, carbocycloalkyl,heterocarbocyclyl, heterocarbocycloalkyl, aryl, arylalkyl, heteroaryl,heteroarylalkyl.

The term “optionally substituted,” as used herein, means thatsubstitution is optional and therefore it is possible for the designatedatom to be unsubstituted.

As used herein, “salts” refer to derivatives of the disclosed compoundswhere the parent compound is modified making acid or base salts thereof.Examples of salts include, but are not limited to, mineral or organicacid salts of basic residues such as amines, alkylamines, ordialkylamines; alkali or organic salts of acidic residues such ascarboxylic acids; and the like. In typical embodiments, the salts areconventional nontoxic pharmaceutically acceptable salts including thequaternary ammonium salts of the parent compound formed, and non-toxicinorganic or organic acids. Preferred salts include those derived frominorganic acids such as hydrochloric, hydrobromic, sulfuric, sulfamic,phosphoric, nitric and the like; and the salts prepared from organicacids such as acetic, propionic, succinic, glycolic, stearic, lactic,malic, tartaric, citric, ascorbic, pamoic, maleic, hydroxymaleic,phenylacetic, glutamic, benzoic, salicylic, sulfanilic,2-acetoxybenzoic, fumaric, toluenesulfonic, methanesulfonic, ethanedisulfonic, oxalic, isethionic, and the like.

“Subject” refers to any animal, preferably a human patient, livestock,rodent, monkey or domestic pet.

The term “prodrug” refers to an agent that is converted into abiologically active form in vivo. Prodrugs are often useful because, insome situations, they may be easier to administer than the parentcompound. They may, for instance, be bioavailable by oral administrationwhereas the parent compound is not. The prodrug may also have improvedsolubility in pharmaceutical compositions over the parent drug. Aprodrug may be converted into the parent drug by various mechanisms,including enzymatic processes and metabolic hydrolysis.

Typical prodrugs are pharmaceutically acceptable esters. Prodrugsinclude compounds wherein a hydroxyl, amino or mercapto group is bondedto any group that, when the prodrug of the active compound isadministered to a subject, cleaves to form a free hydroxy, free amino orfree mercapto group, respectively. Examples of prodrugs include, but arenot limited to, acetate, formate and benzoate derivatives of an alcoholor acetamide, formamide and benzamide derivatives of an amine functionalgroup in the active compound and the like.

As used herein, “pharmaceutically acceptable esters” include, but arenot limited to, alkyl, alkenyl, alkynyl, aryl, arylalkyl, and cycloalkylesters of acidic groups, including, but not limited to, carboxylicacids, phosphoric acids, phosphinic acids, sulfonic acids, sulfinicacids, and boronic acids.

As used herein, the term “derivative” refers to a structurally similarcompound that retains sufficient functional attributes of the identifiedanalogue. The derivative may be structurally similar because it islacking one or more atoms, substituted with one or more substituents, asalt, in different hydration/oxidation states, e.g., substituting asingle or double bond, substituting a hydroxyl group for a ketone, orbecause one or more atoms within the molecule are switched, such as, butnot limited to, replacing an oxygen atom with a sulfur or nitrogen atomor replacing an amino group with a hydroxyl group or vice versa.Replacing a carbon with nitrogen in an aromatic ring is a contemplatedderivative. The derivative may be a prodrug. Derivatives may be preparedby any variety of synthetic methods or appropriate adaptations presentedin the chemical literature or as in synthetic or organic chemistry textbooks, such as those provide in March's Advanced Organic Chemistry:Reactions, Mechanisms, and Structure, Wiley, 6th Edition (2007) MichaelB. Smith or Domino Reactions in Organic Synthesis, Wiley (2006) Lutz F.Tietze hereby incorporated by reference.

As used herein, the terms “prevent” and “preventing” include theprevention of the recurrence, spread or onset. It is not intended thatthe present disclosure be limited to complete prevention. In someembodiments, the onset is delayed, or the severity of the disease isreduced.

As used herein, the terms “treat” and “treating” are not limited to thecase where the subject (e.g., patient) is cured and the disease iseradicated. Rather, embodiments of the present disclosure alsocontemplate treatment that merely reduces symptoms, and/or delaysdisease progression.

As used herein, the term “effective amount” of a compound, with respectto the administration for treatment or preventative methods, refers toan amount of the compound which, when delivered as part of desired doseregimen, brings about management of the disease or disorder toclinically acceptable standards considering a subject physicalattributes such as weight, age, etc.

As used herein, the term “combination with” when used to describeadministration with an additional treatment means that the agent may beadministered prior to, together with, or after the additional treatment,or a combination thereof.

The term “CFTR” refers to refers to the naturally occurring molecule inhumans identified as having (SEQ ID NO: 1) of variants thereof.

MQRSPLEKASVVSKLFFSWTRPILRKGYRQRLELSDIYQIPSVDSADNLSEKLEREWDRELASKKNPKLINALRRCFFWRFMFYGIFLYLGEVTKAVQPLLLGRIIASYDPDNKEERSIAIYLGIGLCLLFIVRTLLLHPAIFGLHHIGMQMRIAMFSLIYKKTLKLSSRVLDKISIGQLVSLLSNNLNKFDEGLALAHFVWIAPLQVALLMGLIWELLQASAFCGLGFLIVLALFQAGLGRMMMKYRDQRAGKISERLVITSEMIENIQSVKAYCWEEAMEKMIENLRQTELKLTRKAAYVRYFNSSAFFFSGFFVVFLSVLPYALIKGIILRKIFTTISFCIVLRMAVTRQFPWAVQTWYDSLGAINKIQDFLQKQEYKTLEYNLTTTEVVMENVTAFWEEGFGELFEKAKQNNNNRKTSNGDDSLFFSNFSLLGTPVLKDINFKIERGQLLAVAGSTGAGKTSLLMVIMGELEPSEGKIKHSGRISFCSQFSWIMPGTIKENIIFGVSYDEYRYRSVIKACQLEEDISKFAEKDNIVLGEGGITLSGGQRARISLARAVYKDADLYLLDSPFGYLDVLTEKEIFESCVCKLMANKTRILVTSKMEHLKKADKILILHEGSSYFYGTFSELQNLQPDFSSKLMGCDSFDQFSAERRNSILTETLHRFSLEGDAPVSWTETKKQSFKQTGEFGEKRKNSILNPINSIRKFSIVQKTPLQMNGIEEDSDEPLERRLSLVPDSEQGEAILPRISVISTGPTLQARRRQSVLNLMTHSVNQGQNIHRKTTASTRKVSLAPQANLTELDIYSRRLSQETGLEISEEINEEDLKECFFDDMESIPAVTTWNTYLRYITVHKSLIFVLIWCLVIFLAEVAASLVVLWLLGNTPLQDKGNSTHSRNNSYAVIITSTSSYYVFYIYVGVADTLLAMGFFRGLPLVHTLITVSKILHHKMLHSVLQAPMSTLNTLKAGGILNRFSKDIAILDDLLPLTIFDFIQLLLIVIGAIAVVAVLQPYIFVATVPVIVAFIMLRAYFLQTSQQLKQLESEGRSPIFTHLVTSLKGLWTLRAFGRQPYFETLFHKALNLHTANWFLYLSTLRWFQMRIEMIFVIFFIAVTFISILTTGEGEGRVGIILTLAMNIMSTLQWAVNSSIDVDSLMRSVSRVFKFIDMPTEGKPTKSTKPYKNGQLSKVMIIENSHVKKDDIWPSGGQMTVKDLTAKYTEGGNAILENISFSISPGQRVGLLGRTGSGKSTLLSAFLRLLNTEGEIQIDGVSWDSITLQQWRKAFGVIPQKVFIFSGTFRKNLDPYEQWSDQEIWKVADEVGLRSVIEQFPGKLDFVLVDGGCVLSHGHKQLMCLARSVLSKAKILLLDEPSAHLDPVTYQIIRRTLKQAFADCTVILCEHRIEAMLECQQFLVIEENKVRQYDSIQKLLNERSLFRQAISPSDRVKLFPHRNSSKCKSKPQIAALKEETEEEVQDTRL.Managing Cystic Fibrosis Transmembrane Conductance Regulator (CFTR)Protein Mediated Diseases or Conditions Cystic fibrosis (CF) is causedby mutations in the cystic fibrosis transmembrane conductance regulator(CFTR). CFTR is a member of the ABC Transporter Superfamily, andfunctions as a chloride ion channel. Experimental data and availablehomology models suggest that CFTR contains five major functionaldomains: two membrane-spanning domains (MSDs) with six transmembranehelices (TM) in each MSD, two nucleotide-binding domains (NBD1, NBD2),and a unique regulatory (R) domain containing multiple protein kinase A(PKA) and C (PKC) consensus sites. In addition to the human gene, CFTRclones have been produced from other species, including Xenopus laevis(frog), pig, mouse, and sheep.

CFTR is regulated by ATP and PKA. The activities of CFTR channels can bemodulated by certain compounds. These could be broadly divided into CFTRpotentiators, CFTR correctors, and CFTR blockers. Some CFTR blockershave also been found to bear potentiator function. These includeGlyH-101, NPPB, and glibenclamide. NPPB, a hCFTR blocker, was discoveredto potentiate hCFTR when the channel is incompletely phosphorylated,i.e., when activated by a low concentration of PKA. Extremely highconcentrations of NPPB were also reported to potentiate hCFTR. The hCFTRblockers GlyH-101 and glibenclamide also potentiate mCFTR.

Efforts towards the development of CFTR potentiators have led to theidentification of the drug with the generic name ivacaftor (also calledVX-770 with the trade name Kalydeco™). Ivacaftor is also approved incombination with lumacaftor for patients who have deletion of the codonfor phenylalanine (F) at position 508, referred to as the F508 delmutation, which is the most common CFTR mutation found in patients.Having the F508 del mutation reduces escape of CFTR from the endoplasmicreticulum. Lumacaftor is reported to increase the trafficking of CFTR tothe cell surface.

Mutations in the CFTR gene result in absence or dysfunction of theprotein that regulates ion transport across the apical membrane at thesurface of certain epithelia. Although CFTR functions mainly as achloride channel, it has other roles, including inhibition of sodiumtransport through the epithelial sodium channel, regulation of theoutwardly rectifying chloride channel, intracellular vesicle transport,and inhibition of endogenous calcium-activated chloride channels. CFTRis also involved in bicarbonate transport. A deficiency in bicarbonatesecretion leads to poor solubility and aggregation of luminal mucins.Obstruction of intrapancreatic ducts with thickened secretions causesautolysis of pancreatic tissue with replacement of the body of thepancreas with fat, leading to pancreatic insufficiency with subsequentmalnutrition. In the lungs, CFTR dysfunction leads to airway surfaceliquid (ASL) depletion and thickened and viscous mucus that adheres toairway surfaces. The result is decreased mucociliary clearance (MCC) andimpaired host defenses. Dehydrated, thickened secretions lead toendobronchial infection with a limited spectrum of distinctive bacteria,mainly Staphylococcus aureus and Pseudomonas aeruginosa, and anexaggerated inflammatory response leading to development ofbronchiectasis and progressive obstructive airways disease. Pulmonaryinsufficiency is responsible for most CF-related deaths.

Although it is not intended that embodiments of this disclosure belimited by any particular mechanism, a compound disclosed herein mayincrease chloride transport of a CFTR protein in a cell by increasingthe CFTR protein channel gating, by increasing the amount of CFTRprotein that is trafficked to the cell surface, or a combinationthereof. In some embodiments, the compound increases chloride transportby increasing the amount of CFTR protein that is trafficked to the cellsurface. In some embodiments, the compound increases chloride transportby both increasing the CFTR protein channel gating or open time, and byincreasing the amount of CFTR protein that is trafficked to the cellsurface.

Compounds of this disclosure are useful as modulators of CFTR andtreating diseases or disorders mediated by CFTR such as for thetreatment of disease, disorders or conditions such as cystic fibrosis,asthma, constipation, pancreatitis, gastrointestinal diseases ordisorders, infertility, hereditary emphysema, hereditaryhemochromatosis, coagulation-fibrinolysis deficiencies, such as proteinC deficiency, type 1 hereditary angioedema, lipid processingdeficiencies, such as familial hypercholesterolemia, type 1chylomicronemia, abetalipoproteinemia, lysosomal storage diseases, suchas I-cell disease/Pseudo-Hurler, mucopolysaccharidoses,Sandhof/Tay-Sachs, Crigler-Najjar type II, polyendocrinopathy,hyperinsulemia, diabetes mellitus, laron dwarfism, myeloperoxidasedeficiency, primary hypoparathyroidism, melanoma, glycanosis CDG type 1,congenital hyperthyroidism, osteogenesis imperfecta, hereditaryhypofibrinogenemia, ACT deficiency, diabetes insipidus (DI),neurophyseal DI, neprogenic DI, Charcot-Marie tooth syndrome,Perlizaeus-Merzbacher disease, neurodegenerative diseases such asAlzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis,progressive supranuclear palsy, Pick's disease, several polyglutamineneurological disorders such as Huntington's disease, spinocerebullarataxia type I, spinal and bulbar muscular atrophy, dentororubalpallidoluysian, and myotic dystrophy, as well as spongiformencephalopathies such as secretory diarrhea, polycystic kidney disease,chronic obstructive pulmonary disease (COPD), dry eye disease, orSjogren's Syndrome, spongiform encephalopathies, such as hereditaryCreutzfeldt-Jakob disease (due to Prion protein processing defect),Fabry disease, and Straussler-Scheinker syndrome.

With respect to a compound or combinations of compounds ability topotentiate or increase chloride transport of a CFTR protein, this may bedetermined by utilizing standard assays known in the art, including, butnot limited to, the utilization of Ussing chamber recordings and animalmodels. Ussing chamber assays use electrodes to measure ion flow acrossthe membranes of cells grown into a monolayer with tight junctions. Oneobtains and grows primary CF airway epithelial cells. Two days before anUssing assay, one aspirates the mucus on the apical surface of thecells. One day before the Ussing assay test, one adds compounds to thebasolateral surface of the cells at various test concentrationsdissolved in solution. For the Ussing experiment, one pre-equilibrates acell containing chamber buffer solution on both apical and basolateralsides by bubbling with room air to facilitate mixing upon addition ofcompounds. One records a resting current to ensure a stable baseline.One blocks the resting current by the apical addition of benzamil, anENaC inhibitor. After several minutes, one adds forskolin to both theapical and basolateral side to stimulate CFTR. One detects an increasein chloride current as an upward deflection of the trace. After anadditional amount of time, one adds a test compound wherein apotentiator further increasing the chloride current.

The methods and compounds described herein may be tested in any one ofseveral animal models in order to further characterize the compound, orin order to optimize dosing or for the generation of formulations.

Mouse models having null or mutant forms of CFTR exist. See, e.g.,Fisher et al., 2011, Methods Mol Biol, 742:311-34. These mouse modelsrecapitulate various CF-related organ pathologies to varying degrees,and the severity of the phenotypes of these mice are generally based onthe amounts of CFTR mRNA present. Most of the mouse models displayphenotypes such as severe abnormalities of the gastrointestinal tract,failure to thrive, decreased survival and hyperinflammatory responses inthe airway. These mice also may display defects in cAMP-induciblechloride permeability in the nasal epithelium, decreased mucociliaryclearance, reduced fertility, mild pancreatic dysfunction and liverabnormalities. Typically, these mouse models do not display thesignificant spontaneous lung disease as observed in CF human subjects.

A pig and ferret model of CF have been developed. See, e.g., Keiser, etal., 2011, Curr Opin Pulm Medic, 17: 478-483. These models recapitulatethe CF symptoms observed in human subjects. In particular, a pig havinga CFTR F508del/F508del mutation develops lung disease and severegallbladder disease and displays exocrine pancreatic defects and hepaticlesions. In some embodiments, a compound disclosed herein isadministered to the CFTR F508del/F508del pig, and effects of thecorrector agent on CF-like symptoms are assessed.

Personalized Medicine

In some embodiments, the methods of the disclosure comprises treating asubject having mutation in CFTR of SEQ ID NO: 1. In some embodiments,the subject to be treated with a compound disclosed herein is diagnosedor identified through testing, determining or measuring a nucleic acidor associated protein as having one or more CFTR mutations. In someembodiments the mutations are R352A, E56K, P67L, E92K, R117H, L206Wand/or DELTA F508.

In some embodiments, the methods of the disclosure comprises treating asubject having one or more mutations is at an amino acid positioncorresponding to any one of, or combination of, amino acid residues 92,126, 130, 132, 137, 138, 139, 140, 141, 145, 146, 165, 166, 170, 175,177, 178, 179, 206, 241, 243, 244, 248, 258, 277, 279, 281, 285, 287,353, 355, 356, 357, 360, 361, 364, 365, 360, 373, 375, 378, 379, 383,388, 392, or 394 of SEQ ID NO: 1. In some embodiments, in addition tothe mutations listed, the mutant CFTR protein further comprises amutation at a position corresponding to 508 of SEQ ID NO: 1. In someembodiments the mutation at a position corresponding to 508 of SEQ IDNO: 1 is DELTA F508. In some embodiments, the mutation is selected fromthe group consisting of a substitution of lysine or leucine for glutamicacid at amino acid residue 56 of SEQ ID NO: 1. In some embodiments, themutation is the substitution of leucine for proline at amino acidresidue 67 of SEQ ID NO: 1. In some embodiments, the mutation isselected from the group consisting of a substitution of lysine,glutamine, arginine, valine or aspartic acid for glutamic acid at aminoacid residue 92 of SEQ ID NO: 1. In some embodiments, the mutation isthe substitution of an aspartic acid for glycine at amino acid residue126 of SEQ ID NO: 1. In some embodiments, the mutation is a substitutionof valine for leucine at amino acid residue 130 of SEQ ID NO: 1. In someembodiments, the mutation is a substitution of methionine for isoleucineat amino acid 132 of SEQ ID NO: 1. In some embodiments, the mutation isa substitution of histidine, proline or arginine for leucine at aminoacid 137 residue of SEQ ID NO: 1. In some embodiments, the mutation isan insertion of leucine at amino acid residue 138 of SEQ ID NO: 1. Insome embodiments, the mutation is a substitution of leucine or argininefor histidine at amino acid residue 139 of SEQ ID NO: 1. In someembodiments, the mutation is a substitution of serine or leucine forproline at amino acid residue 140 of SEQ ID NO: 1. In some embodiments,the mutation is a substitution of aspartic acid for alanine at aminoacid residue 141 of SEQ ID NO: 1. In some embodiments, the mutation is asubstitution of histidine for leucine at amino acid residue 145 of SEQID NO: 1. In some embodiments, the mutation is a substitution ofarginine for histidine at amino acid residue 146 of SEQ ID NO: 1. Insome embodiments, the mutation is a substitution of serine for leucineat amino acid residue 165 of SEQ ID NO: 1. In some embodiments, themutation is a substitution of glutamine for lysine at amino acid residue166 of SEQ ID NO: 1. In some embodiments, the mutation is a substitutionof cysteine, glycine, or histidine for arginine at amino acid residue170 of SEQ ID NO: 1. In some embodiments, the mutation is a substitutionof valine for isoleucine at amino acid residue 175 of SEQ ID NO: 1. Insome embodiments, the mutation is a substitution of threonine forisoleucine at amino acid residue 177 of SEQ ID NO: 1. In someembodiments, the mutation is a substitution of glutamic acid or argininefor glycine at amino acid residue 178 of SEQ ID NO: 1. In someembodiments, the mutation is a substitution of lysine for glutamine atamino acid residue 179 of SEQ ID NO: 1. In some embodiments, themutation is a substitution of tryptophan for leucine at amino acidresidue 206 of SEQ ID NO:1. IN some embodiments, the mutation is asubstitution of aspartic acid for valine at amino acid residue 232 ofSEQ ID NO: 1. In some embodiments, the mutation is a substitution ofarginine for glycine at amino acid residue 241 of SEQ ID NO: 1. In someembodiments, the mutation is a substitution of leucine for methionine atamino acid residue 243 of SEQ ID NO: 1. In some embodiments, themutation is a substitution of lysine for methionine at amino acidresidue 244 of SEQ ID NO: 1. In some embodiments, the mutation is asubstitution ofthreonine for arginine at amino acid residue 248 of SEQID NO: 1. In some embodiments, the mutation is a substitution of glycinefor arginine at amino acid residue 258 of SEQ ID NO: 1. In someembodiments, the mutation is a substitution of arginine for tryptophanat amino acid residue 277 of SEQ ID NO: 1. In some embodiments, themutation is a substitution of aspartic acid for glutamic acid at aminoacid residue 279 of SEQ ID NO: 1. In some embodiments, the mutation is asubstitution of threonine for methionine at amino acid residue 281 ofSEQ ID NO: 1. In some embodiments, the mutation is a substitution ofphenylalanine for isoleucine at amino acid residue 285 of SEQ ID NO: 1.In some embodiments, the mutation is a substitution of tyrosine forasparagine at amino acid residue 287 of SEQ ID NO: 1. In someembodiments, the mutation is a substitution of lysine for isoleucine atamino acid residue 336 of SEQ ID NO: 1. In some embodiments, themutation is a substitution of histidine for glutamine at amino acidresidue 353 of SEQ ID NO: 1. In some embodiments, the mutation is asubstitution of serine for proline at amino acid residue 355 of SEQ IDNO: 1. In some embodiments, the mutation is a substitution of serine fortryptophan at amino acid residue 356 of SEQ ID NO: 1. In someembodiments, the mutation is a substitution of lysine or arginine forglutamine at amino acid residue 359 of SEQ ID NO: 1. In someembodiments, the mutation is a substitution of lysine or arginine forthreonine at amino acid residue 360 of SEQ ID NO: 1. In someembodiments, the mutation is a substitution of arginine for tryptophanat amino acid residue 361 of SEQ ID NO: 1. In some embodiments, themutation is a substitution of serine for proline at amino acid residue364 of SEQ ID NO: 1. In some embodiments, the mutation is a substitutionof leucine for proline at amino acid residue 365 of SEQ ID NO: 1. Insome embodiments, the mutation is the insertion of aspartic acid andlysine after amino acid residue 370 of SEQ ID NO: 1. In someembodiments, the mutation is a substitution of glutamic acid foraspartic acid at amino acid residue 373 of SEQ ID NO: 1. In someembodiments, the mutation is a substitution of phenylalanine for leucineat amino acid residue 375 of SEQ ID NO: 1. In some embodiments, themutation is a substitution of arginine for glutamine at amino acidresidue 378 of SEQ ID NO: 1. In some embodiments, the mutation is asubstitution of lysine for glutamic acid at amino acid residue 379 ofSEQ ID NO: 1. In some embodiments, the mutation is a substitution ofserine for leucine at amino acid residue 383 of SEQ ID NO: 1. In someembodiments, the mutation is a substitution of methionine for threonineat amino acid residue 388 of SEQ ID NO: 1. In some embodiments, themutation is a substitution of alanine or glycine for valine at aminoacid residue 392 of SEQ ID NO: 1. In some embodiments, the mutation is asubstitution of arginine for methionine at amino acid residue 394 of SEQID NO: 1. In some embodiments, the mutation is the substation ofglutamic acid for alanine at amino acid residue 455 of SEQ ID NO: 1. Insome embodiments, the mutation is the substitution of aspartic acid forhistidine at amino acid residue 1054 of SEQ ID NO: 1. In someembodiments, the mutation is the substitution of arginine for glycine atamino acid residue 1061 of SEQ ID NO: 1. In some embodiments, themutation is the substitution of histidine for arginine at amino acidresidue 1066 of SEQ ID NO: 1. In some embodiments, the mutation is thesubstitution of leucine for phenylalanine at amino acid residue 1074 ofSEQ ID NO: 1. In some embodiments, the mutation is the substitution ofarginine for histidine at amino acid residue 1085 of SEQ ID NO: 1.

In some embodiments, the methods of the disclosure comprises treating asubject having one or more CFTR mutations selected from G551D, G1244E,G1349D, G178R, G551S, S1251N, S1255P, S549N, or S549R of SEQ ID NO: 1.

Combination Therapies

The compounds of this disclosure may be administered in combination withother pharmaceutical agents such as antibiotics, anti-viral agents,anti-inflammatory agents, bronchodilators, or mucus-thinning medicines.In particular antibiotics for the treatment of bacteria mucoidPseudomonas may be used in combination with compounds disclosed herein.

Inhaled antibiotics such as tobramycin, colistin, and aztreonam can beused in combination for treatment with compounds disclosed herein.Anti-inflammatory medicines may also be used in combination withcompounds disclosed herein to treat CFTR related diseases.Bronchodilators can be used in combination with compounds disclosedherein to treat CFTR related diseases.

In one embodiment, the disclosure relates to combination therapycomprising compounds disclosed herein and other pharmaceutical agentsuseful for the treatment of CF. In a preferred embodiment, theaminoglycoside gentamicin can be used. In a preferred embodiment,ataluren, ivacaftor or lumacaftor may be used in combination withcompounds disclosed herein.

In some embodiments, the method comprises administering to a subject acompound disclosed herein and at least one additional therapeutic agent.In some embodiments, the additional therapeutic agent is abronchodilator, an antibiotic, a mucolytic agent, a nutritional agent oran agent that blocks ubiquitin-mediated proteolysis.

In certain embodiments, a bronchodilator for use as an additionaltherapeutic agent may be a short-acting beta2 agonist, a long-actingbeta2 agonist or an anticholinergic. In some embodiments, thebronchodilator is any one of, or combination of, salbutamol/albuterol,levosalbutamol/levalbuterol, pirbuterol, epinephrine, ephedrine,terbutaline, salmeterol, clenbuterol, formoterol, bambuterol,indacaterol, theophylline, tiotropium or ipratropium bromide.

In certain embodiments, an antibiotic for use as an additionaltherapeutic agent may be any antibiotic chosen by a physician forreducing lung infections in a CF subject. In some embodiments, theantibiotic is any one of, or combination of, xicillin, clavulanatepotassium, aztreonam, ceftazidime, ciprofloxacin, gentamicin ortobramycin.

In certain embodiments, a mucolytic agent for use as an additionaltherapeutic agent may be any agent used for breaking down the gelstructure of mucus and therefore decreasing its elasticity andviscosity. In some embodiments, the mucolytic agent is N-acetylcysteine,dornase alpha, hypertonic solution, mannitol, gelsolin orthymosin-beta4.

A nutritional agent for use as an additional therapeutic agent may beany agent that may be used to promote adequate growth and weight gain ina CF subject. In some embodiments, the nutritional agent is any one of,or combination of, vitamins A, D, E, or K, sodium chloride, calcium, orpancreatic enzymes. In some embodiments, the nutritional agent is amultivitamin. In some embodiments, the nutritional agent is a highcalorie food or food supplement.

An agent that blocks ubiquitin-mediated proteolysis for use as anadditional therapeutic agent is any agent that blocks proteasomaldegradation of misfolded CFTR.

In some embodiments, the agent that blocks ubiquitin-mediatedproteolysis is selected from the group consisting of bortezomib,carfilzomib, and marizomib.

2-Amino-N′-benzylideneacetohydrazide Compounds and Derivatives

A virtual screening of a database of commercially available compoundsled to the identification of compounds with potentiator activity invitro. In certain embodiments, this disclosure relates to2-amino-N′-benzylideneacetohydrazide compounds or derivatives thereof.In certain embodiments, the derivative is a compound of the followingformula:

or salts, esters, prodrug, or derivatives thereof wherein,

R¹ is hydrogen, alkyl, alkenyl, alkynyl, alkanoyl, alkoxyalkyl, halogen,bromo, nitro, cyano, hydroxy, amino, amido, mercapto, formyl, carboxy,carbamoyl, azido, alkoxy, alkylthio, alkylamino, (alkyl)₂amino,alkylsulfinyl, alkylsulfonyl, arylsulfonyl, benzyl, benzoyl,carbocyclyl, aryl, or heterocyclyl, wherein R¹ is optionally substitutedwith one or more, the same or different, R¹⁰;

R² is hydrogen, alkyl, alkenyl, alkynyl, alkanoyl, alkoxyalkyl, halogen,bromo, nitro, cyano, hydroxy, amino, amido, mercapto, formyl, carboxy,carbamoyl, azido, alkoxy, alkylthio, alkylamino, (alkyl)₂amino,alkylsulfinyl, alkylsulfonyl, arylsulfonyl, benzyl, benzoyl,carbocyclyl, aryl, or heterocyclyl, wherein R² is optionally substitutedwith one or more, the same or different, R¹⁰;

R³ is hydrogen, alkyl, alkenyl, alkynyl, alkanoyl, alkoxyalkyl, halogen,bromo, nitro, cyano, hydroxy, amino, amido, mercapto, formyl, carboxy,carbamoyl, azido, alkoxy, alkylthio, alkylamino, (alkyl)₂amino,alkylsulfinyl, alkylsulfonyl, arylsulfonyl, benzyl, benzoyl,carbocyclyl, aryl, or heterocyclyl, wherein R³ is optionally substitutedwith one or more, the same or different, R¹⁰;

R⁴ is hydrogen, alkyl, alkenyl, alkynyl, alkanoyl, alkoxyalkyl, halogen,bromo, nitro, cyano, hydroxy, amino, amido, mercapto, formyl, carboxy,carbamoyl, azido, alkoxy, alkylthio, alkylamino, (alkyl)₂amino,alkylsulfinyl, alkylsulfonyl, arylsulfonyl, benzyl, benzoyl,carbocyclyl, aryl, or heterocyclyl, wherein R⁴ is optionally substitutedwith one or more, the same or different, R¹⁰;

R⁵ is hydrogen, alkyl, alkenyl, alkynyl, alkanoyl, alkoxyalkyl, halogen,bromo, nitro, cyano, hydroxy, amino, amido, mercapto, formyl, carboxy,carbamoyl, azido, alkoxy, alkylthio, alkylamino, (alkyl)₂amino,alkylsulfinyl, alkylsulfonyl, arylsulfonyl, benzyl, benzoyl,carbocyclyl, aryl, or heterocyclyl, wherein R⁵ is optionally substitutedwith one or more, the same or different, R¹⁰;

R⁶ is hydrogen, alkyl, alkenyl, alkynyl, alkanoyl, alkoxyalkyl, halogen,nitro, cyano, hydroxy, amino, amido, mercapto, formyl, carboxy,carbamoyl, azido, alkoxy, alkylthio, alkylamino, (alkyl)₂amino,alkylsulfinyl, alkylsulfonyl, arylsulfonyl, benzyl, benzoyl,carbocyclyl, aryl, or heterocyclyl, wherein R⁶ is optionally substitutedwith one or more, the same or different, R¹⁰; and

R¹⁰ is alkyl, alkenyl, alkynyl, alkanoyl, alkoxyalkyl, halogen, nitro,cyano, hydroxy, amino, amido, mercapto, formyl, carboxy, carbamoyl,azido, alkoxy, alkylthio, alkylamino, (alkyl)2amino, alkylsulfinyl,alkylsulfonyl, arylsulfonyl, benzyl, benzoyl, carbocyclyl, aryl, orheterocyclyl, wherein R¹⁰ is optionally substituted with one or more,the same or different, R¹¹; and

R¹¹ is halogen, nitro, cyano, hydroxy, trifluoromethoxy,trifluoromethyl, amino, formyl, carboxy, carbamoyl, mercapto, sulfamoyl,methyl, ethyl, methoxy, ethoxy, acetyl, acetoxy, methylamino,ethylamino, dimethylamino, diethylamino, N-methyl-N-ethylamino,acetylamino, N-methylcarbamoyl, N-ethylcarbamoyl, N,N-dimethylcarbamoyl,N,N-diethylcarbamoyl, N-methyl-N-ethylcarbamoyl, methylthio, ethylthio,methylsulfinyl, ethylsulfinyl, mesyl, ethylsulfonyl, methoxycarbonyl,ethoxycarbonyl, N-methylsulfamoyl, N-ethylsulfamoyl,N,N-dimethylsulfamoyl, N,N-diethylsulfamoyl, N-methyl-N-ethylsulfamoyl,benzyl, benzoyl, carbocyclyl, aryl, or heterocyclyl.

In certain embodiments, the R¹ is hydrogen.

In certain embodiments, the R⁵ is hydroxyl.

In certain embodiments, the R⁴ is halogen or bromo.

In certain embodiments, the R³ is hydroxyl.

In certain embodiments, the R² is halogen or bromo.

In certain embodiments, the R⁶ phenyl optionally ortho or parasubstituted.

In certain embodiments, this disclosure relates to2-amino-N′-benzylideneacetohydrazide compounds, salts, or derivativesthereof. In certain embodiments, the derivative is a compound of thefollowing formula:

or salts, esters, prodrug, or derivatives thereof wherein,

R¹ is hydrogen, alkyl, alkenyl, alkynyl, alkanoyl, alkoxyalkyl, halogen,bromo, nitro, cyano, hydroxy, amino, amido, mercapto, formyl, carboxy,carbamoyl, azido, alkoxy, alkylthio, alkylamino, (alkyl)₂amino,alkylsulfinyl, alkylsulfonyl, arylsulfonyl, benzyl, benzoyl,carbocyclyl, aryl, or heterocyclyl, wherein R¹ is optionally substitutedwith one or more, the same or different, R¹⁰;

R² is hydrogen, alkyl, alkenyl, alkynyl, alkanoyl, alkoxyalkyl, halogen,bromo, nitro, cyano, hydroxy, amino, amido, mercapto, formyl, carboxy,carbamoyl, azido, alkoxy, alkylthio, alkylamino, (alkyl)₂amino,alkylsulfinyl, alkylsulfonyl, arylsulfonyl, benzyl, benzoyl,carbocyclyl, aryl, or heterocyclyl, wherein R² is optionally substitutedwith one or more, the same or different, R¹⁰;

R³ is hydrogen, alkyl, alkenyl, alkynyl, alkanoyl, alkoxyalkyl, halogen,bromo, nitro, cyano, hydroxy, amino, amido, mercapto, formyl, carboxy,carbamoyl, azido, alkoxy, alkylthio, alkylamino, (alkyl)₂amino,alkylsulfinyl, alkylsulfonyl, arylsulfonyl, benzyl, benzoyl,carbocyclyl, aryl, or heterocyclyl, wherein R³ is optionally substitutedwith one or more, the same or different, R¹⁰;

R⁴ is hydrogen, alkyl, alkenyl, alkynyl, alkanoyl, alkoxyalkyl, halogen,nitro, cyano, hydroxy, amino, amido, mercapto, formyl, carboxy,carbamoyl, azido, alkoxy, alkylthio, alkylamino, (alkyl)₂amino,alkylsulfinyl, alkylsulfonyl, arylsulfonyl, benzyl, benzoyl,carbocyclyl, aryl, or heterocyclyl, wherein R⁴ is optionally substitutedwith one or more, the same or different, R¹⁰;

R⁵ is hydrogen, alkyl, alkenyl, alkynyl, alkanoyl, alkoxyalkyl, halogen,bromo, nitro, cyano, hydroxy, amino, amido, mercapto, formyl, carboxy,carbamoyl, azido, alkoxy, alkylthio, alkylamino, (alkyl)₂amino,alkylsulfinyl, alkylsulfonyl, arylsulfonyl, benzyl, benzoyl,carbocyclyl, aryl, or heterocyclyl, wherein R⁵ is optionally substitutedwith one or more, the same or different, R¹⁰;

R¹⁰ is alkyl, alkenyl, alkynyl, alkanoyl, alkoxyalkyl, halogen, nitro,cyano, hydroxy, amino, amido, mercapto, formyl, carboxy, carbamoyl,azido, alkoxy, alkylthio, alkylamino, (alkyl)2amino, alkylsulfinyl,alkylsulfonyl, arylsulfonyl, benzyl, benzoyl, carbocyclyl, aryl, orheterocyclyl, wherein R¹⁰ is optionally substituted with one or more,the same or different, R¹¹;

R¹¹ is halogen, nitro, cyano, hydroxy, trifluoromethoxy,trifluoromethyl, amino, formyl, carboxy, carbamoyl, mercapto, sulfamoyl,methyl, ethyl, methoxy, ethoxy, acetyl, acetoxy, methylamino,ethylamino, dimethylamino, diethylamino, N-methyl-N-ethylamino,acetylamino, N-methylcarbamoyl, N-ethylcarbamoyl, N,N-dimethylcarbamoyl,N,N-diethylcarbamoyl, N-methyl-N-ethylcarbamoyl, methylthio, ethylthio,methylsulfinyl, ethylsulfinyl, mesyl, ethylsulfonyl, methoxycarbonyl,ethoxycarbonyl, N-methylsulfamoyl, N-ethylsulfamoyl,N,N-dimethylsulfamoyl, N,N-diethylsulfamoyl, N-methyl-N-ethylsulfamoyl,benzyl, benzoyl, carbocyclyl, aryl, or heterocyclyl;

R¹² is hydrogen, alkyl, alkenyl, alkynyl, alkanoyl, alkoxyalkyl,halogen, nitro, cyano, hydroxy, amino, amido, mercapto, formyl, carboxy,carbamoyl, azido, alkoxy, alkylthio, alkylamino, (alkyl)₂amino,alkylsulfinyl, alkylsulfonyl, arylsulfonyl, benzyl, benzoyl,carbocyclyl, aryl, or heterocyclyl, wherein R¹² is optionallysubstituted with one or more, the same or different, R²⁰;

R¹³ is hydrogen, alkyl, alkenyl, alkynyl, alkanoyl, alkoxyalkyl,halogen, nitro, cyano, hydroxy, amino, amido, mercapto, formyl, carboxy,carbamoyl, azido, alkoxy, alkylthio, alkylamino, (alkyl)₂amino,alkylsulfinyl, alkylsulfonyl, arylsulfonyl, benzyl, benzoyl,carbocyclyl, aryl, or heterocyclyl, wherein R¹³ is optionallysubstituted with one or more, the same or different, R²⁰;

R¹⁴ is hydrogen, alkyl, alkenyl, alkynyl, alkanoyl, alkoxyalkyl,halogen, nitro, cyano, hydroxy, amino, amido, mercapto, formyl, carboxy,carbamoyl, azido, alkoxy, alkylthio, alkylamino, (alkyl)₂amino,alkylsulfinyl, alkylsulfonyl, arylsulfonyl, benzyl, benzoyl,carbocyclyl, aryl, or heterocyclyl, wherein R¹⁴ is optionallysubstituted with one or more, the same or different, R²⁰;

R¹⁵ is hydrogen, alkyl, alkenyl, alkynyl, alkanoyl, alkoxyalkyl,halogen, nitro, cyano, hydroxy, amino, amido, mercapto, formyl, carboxy,carbamoyl, azido, alkoxy, alkylthio, alkylamino, (alkyl)₂amino,alkylsulfinyl, alkylsulfonyl, arylsulfonyl, benzyl, benzoyl,carbocyclyl, aryl, or heterocyclyl, wherein R¹⁵ is optionallysubstituted with one or more, the same or different, R²⁰;

R¹⁶ is hydrogen, alkyl, alkenyl, alkynyl, alkanoyl, alkoxyalkyl,halogen, nitro, cyano, hydroxy, amino, amido, mercapto, formyl, carboxy,carbamoyl, azido, alkoxy, alkylthio, alkylamino, (alkyl)₂amino,alkylsulfinyl, alkylsulfonyl, arylsulfonyl, benzyl, benzoyl,carbocyclyl, aryl, or heterocyclyl, wherein R¹⁶ is optionallysubstituted with one or more, the same or different, R²⁰;

R²⁰ is alkyl, alkenyl, alkynyl, alkanoyl, alkoxyalkyl, halogen, nitro,cyano, hydroxy, amino, amido, mercapto, formyl, carboxy, carbamoyl,azido, alkoxy, alkylthio, alkylamino, (alkyl)2amino, alkylsulfinyl,alkylsulfonyl, arylsulfonyl, benzyl, benzoyl, carbocyclyl, aryl, orheterocyclyl, wherein R²⁰ is optionally substituted with one or more,the same or different, R²¹; and

R²¹ is halogen, nitro, cyano, hydroxy, trifluoromethoxy,trifluoromethyl, amino, formyl, carboxy, carbamoyl, mercapto, sulfamoyl,methyl, ethyl, methoxy, ethoxy, acetyl, acetoxy, methylamino,ethylamino, dimethylamino, diethylamino, N-methyl-N-ethylamino,acetylamino, N-methylcarbamoyl, N-ethylcarbamoyl, N,N-dimethylcarbamoyl,N,N-diethylcarbamoyl, N-methyl-N-ethylcarbamoyl, methylthio, ethylthio,methylsulfinyl, ethylsulfinyl, mesyl, ethylsulfonyl, methoxycarbonyl,ethoxycarbonyl, N-methylsulfamoyl, N-ethylsulfamoyl,N,N-dimethylsulfamoyl, N,N-diethylsulfamoyl, N-methyl-N-ethylsulfamoyl,benzyl, benzoyl, carbocyclyl, aryl, or heterocyclyl.

In certain embodiments, the R¹ is hydrogen.

In certain embodiments, the R⁵ is hydroxyl.

In certain embodiments, the R⁴ is halogen or bromo.

In certain embodiments, the R³ is hydroxyl.

In certain embodiments, the R² is halogen or bromo.

In certain embodiments, the R¹² is hydrogen.

In certain embodiments, the R¹³ is hydrogen or alkyl.

In certain embodiments, the R¹⁴ is hydrogen or alkyl.

In certain embodiments, the R⁵ is hydrogen or alkyl.

In certain embodiments, the R¹⁶ is hydrogen.

In certain embodiments, the compound is((E)-N′-(3,5-dibromo-2,4-dihydroxybenzylidene)-2-(m-tolylamino)acetohydrazide;or

(E)-N′-(3,5-dibromo-2,4-dihydroxybenzylidene)-2-(p-tolylamino)acetohydrazide.

Formulations

Pharmaceutical compositions disclosed herein may be in the form ofpharmaceutically acceptable salts, as generally described below. Somepreferred, but non-limiting examples of suitable pharmaceuticallyacceptable organic and/or inorganic acids are hydrochloric acid,hydrobromic acid, sulfuric acid, nitric acid, acetic acid and citricacid, as well as other pharmaceutically acceptable acids known per se(for which reference is made to the references referred to below).

When the compounds of the disclosure contain an acidic group as well asa basic group, the compounds of the disclosure may also form internalsalts, and such compounds are within the scope of the disclosure. When acompound of the disclosure contains a hydrogen-donating heteroatom(e.g., NH), the disclosure also covers salts and/or isomers formed bythe transfer of the hydrogen atom to a basic group or atom within themolecule.

Pharmaceutically acceptable salts of the compounds include the acidaddition and base salts thereof. Suitable acid addition salts are formedfrom acids, which form non-toxic salts. Examples include the acetate,adipate, aspartate, benzoate, besylate, bicarbonate/carbonate,bisulphate/sulphate, borate, camsylate, citrate, cyclamate, edisylate,esylate, formate, fumarate, gluceptate, gluconate, glucuronate,hexafluorophosphate, hibenzate, hydrochloride/chloride,hydrobromide/bromide, hydroiodide/iodide, isethionate, lactate, malate,maleate, malonate, mesylate, methylsulphate, naphthylate, 2-napsylate,nicotinate, nitrate, orotate, oxalate, palmitate, pamoate,phosphate/hydrogen phosphate/dihydrogen phosphate, pyroglutamate,saccharate, stearate, succinate, tannate, tartrate, tosylate,trifluoroacetate and xinofoate salts. Suitable base salts are formedfrom bases, which form non-toxic salts. Examples include the aluminium,arginine, benzathine, calcium, choline, diethylamine, diolamine,glycine, lysine, magnesium, meglumine, olamine, potassium, sodium,tromethamine and zinc salts. Hemisalts of acids and bases may also beformed, for example, hemisulphate and hemicalcium salts. For a review onsuitable salts, see Handbook of Pharmaceutical Salts: Properties,Selection, and Use by Stahl and Wermuth (Wiley-VCH, 2002), incorporatedherein by reference.

The compounds described herein may be administered in the form ofprodrugs. A prodrug can include a covalently bonded carrier, whichreleases the active parent drug when administered to a mammaliansubject. Prodrugs can be prepared by modifying functional groups presentin the compounds in such a way that the modifications are cleaved,either in routine manipulation or in vivo, to the parent compounds.Prodrugs include, for example, compounds wherein a hydroxyl group isbonded to any group that, when administered to a mammalian subject,cleaves to form a free hydroxyl group. Examples of prodrugs include, butare not limited to, acetate, formate and benzoate derivatives of alcoholfunctional groups in the compounds. Methods of structuring a compound asprodrug can be found in the book of Testa and Mayer, Hydrolysis in Drugand Prodrug Metabolism, Wiley (2006). Typical prodrugs form the activemetabolite by transformation of the prodrug by hydrolytic enzymes, thehydrolysis of amide, lactams, peptides, carboxylic acid esters, epoxidesor the cleavage of esters of inorganic acids. It is well within theordinary skill of the art to make an ester prodrug, e.g., acetyl esterof a free hydroxyl group. It is well known that ester prodrugs arereadily degraded in the body to release the corresponding alcohol. Seee.g., Imai, Drug Metab Pharmacokinet. (2006) 21(3):173-85, entitled“Human carboxylesterase isozymes: catalytic properties and rational drugdesign.”

Pharmaceutical compositions for use in the present disclosure typicallycomprise an effective amount of a compound and a suitable pharmaceuticalacceptable carrier. The preparations may be prepared in a manner knownper se, which usually involves mixing at least one compound according tothe disclosure with one or more pharmaceutically acceptable carriers,and, if desired, in combination with other pharmaceutical activecompounds, when necessary under aseptic conditions. Reference is made toU.S. Pat. Nos. 6,372,778, 6,369,086, 6,369,087 and 6,372,733 and thefurther references mentioned above, as well as to the standardhandbooks, such as the latest edition of Remington's PharmaceuticalSciences.

Generally, for pharmaceutical use, the compounds may be formulated as apharmaceutical preparation comprising at least one compound and at leastone pharmaceutically acceptable carrier, diluent or excipient, andoptionally one or more further pharmaceutically active compounds.

In certain embodiments, the pharmaceutical composition is in the form ofa pill, tablet, capsule, gel, or particles. In certain embodiments, thepharmaceutical composition is in liquid form comprising oils, fattyacids, saturated or unsaturated hydrocarbons, or an aqueous buffer, e.g.phosphate buffer optionally comprising saline and/or a saccharide orpolysaccharide.

The pharmaceutical preparations of the disclosure are preferably in aunit dosage form, and may be suitably packaged, for example in a box,blister, vial, bottle, sachet, ampoule or in any other suitablesingle-dose or multi-dose holder or container (which may be properlylabeled); optionally with one or more leaflets containing productinformation and/or instructions for use. Generally, such unit dosageswill contain between 1 and 1000 mg, and usually between 5 and 500 mg, ofat least one compound of the disclosure, e.g., about 10, 25, 50, 100,200, 300 or 400 mg per unit dosage.

The compounds can be administered by a variety of routes including oral,ocular, rectal, transdermal, subcutaneous, intravenous, intramuscular orintranasal routes, depending mainly on the specific preparation used.The compound will generally be administered in an “effective amount”, bywhich is meant any amount of a compound that, upon suitableadministration, is sufficient to achieve the desired therapeutic orprophylactic effect in the subject to which it is administered. Usually,depending on the condition to be prevented or treated and the route ofadministration, such an effective amount will usually be between 0.01 to1000 mg per kilogram body weight of the patient per day, more oftenbetween 0.1 and 500 mg, such as between 1 and 250 mg, for example about5, 10, 20, 50, 100, 150, 200 or 250 mg, per kilogram body weight of thepatient per day, which may be administered as a single daily dose,divided over one or more daily doses. The amount(s) to be administered,the route of administration and the further treatment regimen may bedetermined by the treating clinician, depending on factors such as theage, gender and general condition of the patient and the nature andseverity of the disease/symptoms to be treated. Reference is made toU.S. Pat. Nos. 6,372,778, 6,369,086, 6,369,087 and 6,372,733 and thefurther references mentioned above, as well as to the standardhandbooks, such as the latest edition of Remington's PharmaceuticalSciences.

For an oral administration form, the compound can be mixed with suitableadditives, such as excipients, stabilizers or inert diluents, andbrought by means of the customary methods into the suitableadministration forms, such as tablets, coated tablets, hard capsules,aqueous, alcoholic, or oily solutions. Examples of suitable inertcarriers are gum arabic, magnesia, magnesium carbonate, potassiumphosphate, lactose, glucose, or starch, in particular, cornstarch. Inthis case, the preparation can be carried out both as dry and as moistgranules. Suitable oily excipients or solvents are vegetable or animaloils, such as sunflower oil or cod liver oil. Suitable solvents foraqueous or alcoholic solutions are water, ethanol, sugar solutions, ormixtures thereof. Polyethylene glycols and polypropylene glycols arealso useful as further auxiliaries for other administration forms. Asimmediate release tablets, these compositions may containmicrocrystalline cellulose, dicalcium phosphate, starch, magnesiumstearate and lactose and/or other excipients, binders, extenders,disintegrants, diluents and lubricants known in the art.

When administered by nasal aerosol or inhalation, the compositions maybe prepared according to techniques well-known in the art ofpharmaceutical formulation and may be prepared as solutions in saline,employing benzyl alcohol or other suitable preservatives, absorptionpromoters to enhance bioavailability, fluorocarbons, and/or othersolubilizing or dispersing agents known in the art. Suitablepharmaceutical formulations for administration in the form of aerosolsor sprays are, for example, solutions, suspensions or emulsions of thecompounds of the disclosure or their physiologically tolerable salts ina pharmaceutically acceptable solvent, such as ethanol or water, or amixture of such solvents. If required, the formulation may additionallycontain other pharmaceutical auxiliaries such as surfactants,emulsifiers and stabilizers as well as a propellant.

In certain embodiments, the pharmaceutical composition comprises acompound disclosed herein and a propellant. In certain embodiments, anaerosolizing propellant is compressed air, ethanol, nitrogen, carbondioxide, nitrous oxide, hydrofluoroalkanes (HFAs),1,1,1,2,-tetrafluoroethane, 1,1,1,2,3,3,3-heptafluoropropane orcombinations thereof.

In certain embodiments, the disclosure contemplates a pressurized orunpressurized container comprising a compound herein. In certainembodiments, the container is a manual pump spray, inhaler, meter-dosedinhaler, dry powder inhaler, nebulizer, vibrating mesh nebulizer, jetnebulizer, or ultrasonic wave nebulizer.

Suitable topical formulations include, but are not limited to, lotions,ointments, creams, and gels. In a preferred embodiment, the topicalformulation is a gel. In another embodiment, the formulation isadministered intranasally.

For subcutaneous or intravenous administration, the compounds, ifdesired with the substances customary therefore such as solubilizers,emulsifiers or further auxiliaries are brought into solution,suspension, or emulsion. The compounds may also be lyophilized and thelyophilizates obtained used, for example, for the production ofinjection or infusion preparations. Suitable solvents are, for example,water, physiological saline solution or alcohols, e.g. ethanol,propanol, glycerol, sugar solutions such as glucose or mannitolsolutions, or mixtures of the various solvents mentioned. The injectablesolutions or suspensions may be formulated according to known art, usingsuitable non-toxic, parenterally-acceptable diluents or solvents, suchas mannitol, 1,3-butanediol, water, Ringer's solution or isotonic sodiumchloride solution, or suitable dispersing or wetting and suspendingagents, such as sterile, bland, fixed oils, including synthetic mono- ordiglycerides, and fatty acids, including oleic acid.

In certain embodiments, it is contemplated that these compositions canbe extended release formulations. Typical extended release formationsutilize an enteric coating. Typically, a barrier is applied to oralmedication that controls the location in the digestive system where itis absorbed. Enteric coatings prevent release of medication before itreaches the small intestine. Enteric coatings may contain polymers ofpolysaccharides, such as maltodextrin, xanthan, scleroglucan dextran,starch, alginates, pullulan, hyaloronic acid, chitin, chitosan and thelike; other natural polymers, such as proteins (albumin, gelatin etc.),poly-L-lysine; sodium poly(acrylic acid);poly(hydroxyalkylmethacrylates) (for example poly(hydroxyethylmethacrylate)); carboxypolymethylene (for example Carbopol™); carbomer;polyvinyl pyrrolidone; gums, such as guar gum, gum arabic, gum karaya,gum ghatti, locust bean gum, tamarind gum, gellan gum, gum tragacanth,agar, pectin, gluten and the like; poly(vinyl alcohol); ethylene vinylalcohol; polyethylene glycol (PEG); and cellulose ethers, such ashydroxymethyl cellulose (HMC), hydroxyethylcellulose (HEC),hydroxypropylcellulose (HPC), methylcellulose (MC), ethylcellulose (EC),carboxyethylcellulose (CEC), ethylhydroxy ethylcellulose (EHEC),carboxymethylhydroxyethylcellulose (CMHEC),hydroxypropylmethyl-cellulose (HPMC), hydroxypropylethylcellulose (HPEC)and sodium carboxymethylcellulose (Na CMC); as well as copolymers and/or(simple) mixtures of any of the above polymers.

Certain of the above-mentioned polymers may further be crosslinked byway of standard techniques. The choice of polymer will be determined bythe nature of the active ingredient/drug that is employed in thecomposition of the disclosure as well as the desired rate of release. Inparticular, it will be appreciated by the skilled person, for example inthe case of HPMC, that a higher molecular weight will, in general,provide a slower rate of release of drug from the composition.Furthermore, in the case of HPMC, different degrees of substitution ofmethoxy groups and hydroxypropoxy groups will give rise to changes inthe rate of release of drug from the composition. In this respect, andas stated above, it may be desirable to provide compositions of thedisclosure in the form of coatings in which the polymer carrier isprovided by way of a blend of two or more polymers of, for example,different molecular weights in order to produce a particular required ordesired release profile.

Microspheres of polylactide, polyglycolide, and their copolymerspoly(lactide-co-glycolide) may be used to form sustained-release proteindelivery systems. Proteins can be entrapped in thepoly(lactide-co-glycolide) microsphere depot by a number of methods,including formation of a water-in-oil emulsion with water-borne proteinand organic solvent-borne polymer (emulsion method), formation of asolid-in-oil suspension with solid protein dispersed in a solvent-basedpolymer solution (suspension method), or by dissolving the protein in asolvent-based polymer solution (dissolution method). One can attachpoly(ethylene glycol) to proteins (PEGylation) to increase the in vivohalf-life of circulating therapeutic proteins and decrease the chance ofan immune response.

In certain embodiments, the disclosure relates to pharmaceuticalcomposition comprising a compounds disclosed herein and apharmaceutically acceptable excipient, such as a pharmaceuticallyacceptable excipient selected from lactose, sucrose, mannitol, triethylcitrate, dextrose, cellulose, methyl cellulose, ethyl cellulose,hydroxyl propyl cellulose, hydroxypropyl methylcellulose,carboxymethylcellulose, croscarmellose sodium, polyvinyl N-pyrrolidone,crospovidone, ethyl cellulose, povidone, methyl and ethyl acrylatecopolymer, polyethylene glycol, fatty acid esters of sorbitol, laurylsulfate, gelatin, glycerin, glyceryl monooleate, silicon dioxide,titanuium dioxide, talc, corn starch, carnuba wax, stearic acid, sorbicacid, magnesium stearate, calcium stearate, castor oil, mineral oil,calcium phosphate, starch, carboxymethyl ether of starch, iron oxide,triacetin, acacia gum, esters or salts thereof.

EXAMPLES

Work on certain inventions in this disclosure was supported by grantsfrom the Cystic Fibrosis Foundation.

Testing of Compounds

The effects of OSSK-2 and OSSK-3 on hCFTR were tested by expression inXenopus oocytes. Representative current traces using the two-electrodevoltage clamp technique (TEVC) are shown in FIGS. 2A and 2B for OSSK-3and FIG. 2C for OSSK-2. OSSK-3 exhibited both block as well aspotentiation of hCFTR during a ˜50 s extracellular exposure. At VM=−60mV, the apparent Kd for block of hCFTR was 33.0 μM and the apparent Kdfor potentiation of hCFTR was 31.7 nM. Under the same protocol, OSSK-2exhibited very weak block on hCFTR without obvious potentiation. Theapparent Kd for block of hCFTR at VM=−60 mV was 71.3 M.

Nearly 90% of CF patients in the United States bear at least oneF508del-CFTR allele; OSSK-3, and OSSK-2 were studied on F508del-hCFTRusing the TEVC technique at VM=−60 mV. Oocytes do not exhibit theimpaired trafficking of F508del-hCFTR to the plasma membrane (Drumm etal., Science, 1991, 254(5039): 1797-1799). At VM=−60 mV, a ˜50sextracellular exposure to 5 μM OSSK-3 caused very weak initial blockthat was followed by significantly stronger potentiation compared to thepotentiation of WT-hCFTR (FIG. 3A). Similar results were found with 5 μMOSSK-2 (FIG. 3B). The data suggest that like VX-770, which only mildlypotentiates WT-hCFTR but strongly potentiates multiple CFTR mutations,OSSK-2, and OSSK-3 mildly potentiate WT-hCFTR but very stronglypotentiate F508del-hCFTR (See FIGS. 4A and 4B, under modifiedconditions).

Preparation of Oocytes and cRNA and Electrophysiology

Human CFTR cRNAs used in electrophysiology experiments were preparedfrom constructs encoding WT-hCFTR in the pGEMHE vector (hCFTR/pGEMHEkindly provided by Dr. D. Gadsby, Rockefeller University). The mutantsof hCFTR used in this study were prepared using site-directedmutagenesis with the Quikchange protocol (Stratagene, La Jolla, Calif.)and mutant constructs were verified by sequencing across the entire openreading frame before use. Xenopus laevis oocytes were injected with0.4-10 ng of CFTR cRNAs, and were incubated at 17° C. in modifiedLiebovitz's L-15 media with the addition of HEPES (pH 7.5), penicillin,and streptomycin. Recordings were made typically 24-96 hours after theinjection of cRNAs.

For inside-out macropatch recording, pipettes were pulled fromborosilicate glass (Sutter Instrument Co., Novato, Calif.) and pipetteresistances were 1-2 MΩ when filled with chloride-containing pipettesolution (in mM): 150 NMDG-Cl, 5 MgCl2, 10 TES (pH 7.5). Channels wereactivated by excision into cytoplasmic solution containing (in mM): 150NMDG-Cl, 1.1 MgCl₂, 2 Tris-EGTA, 10 TES, 1 MgATP (Adenosine5′-triphosphate magnesium), and different concentrations of PKA (pH7.5). CFTR channels were studied in excised, inside-out patches at roomtemperature (22-23° C.). Oocytes were prepared for study by shrinking inhypertonic solution followed by manual removal of the vitellinemembrane. Macropatch recordings were performed with an Axopatch 200Bamplifier operated by pClamp 8.2 software; data were filtered at 100 Hzwith a four-pole Bessel filter and acquired at 2 kHz. The voltageprotocol used in this project was applied every 5 s: hold at Vm=0 mV,then step to +100 mV for 50 ms followed by a ramp down to −100 mV over300 ms prior to return to 0 mV.

Standard two-electrode voltage clamp (TEVC) techniques were used tostudy the effects of chemicals with application of reagents to theextracellular bath. Each oocyte was injected with CFTR cRNA along withcRNA encoding the beta2-adrenergic receptor (β2AR). Electroderesistances measured 0.5-1.4 MΩ when filled with 3 M KCl and measured instandard ND96 bath solution that contained (in mM): 96 NaCl, 2 KCl, 1MgCl₂, and 5 HEPES (pH 7.5). CFTR channels were activated by exposure to10 μM isoproterenol (ISO) in ND 96 and alternatively assayed in thepresence or absence of different concentrations of compounds in the bathsolution, typically in the continuing presence of ISO. Currents wereacquired with an Axoclamp 900A amplifier and Clampex 10.2 software, andcurrent data were digitized at 2 kHz.

1. A method of treating chronic obstructive pulmonary disease comprisingadministering an effective amount of((E)-N′-(3,5-dibromo-2,4-dihydroxybenzylidene)-2-(m-tolylamino)acetohydrazideor salt thereof to a subject wherein the subject is diagnosed withchronic obstructive pulmonary disease.
 2. The method of claim 1 wherein((E)-N′-(3,5-dibromo-2,4-dihydroxybenzylidene)-2-(m-tolylamino)acetohydrazideor salt thereof is administered in combination with an antibiotic. 3.The method of claim 2 wherein the antibiotic is colistin, clavulanate,aztreonam, ceftazidime, ciprofloxacin, gentamicin, tobramycin, salt orcombination thereof.
 4. The method of claim 1 wherein((E)-N′-(3,5-dibromo-2,4-dihydroxybenzylidene)-2-(m-tolylamino)acetohydrazideor salt thereof is administered in combination with a bronchodilator. 5.The method of claim 4 wherein the bronchodilator is salbutamol,albuterol, levosalbutamol, levalbuterol, pirbuterol, epinephrine,ephedrine, terbutaline, salmeterol, clenbuterol, formoterol, bambuterol,indacaterol, theophylline, tiotropium, ipratropium, salt or combinationsthereof.
 6. A method of treating chronic obstructive pulmonary diseasecomprising administering an effective amount of((E)-N′-(3,5-dibromo-2,4-dihydroxybenzylidene)-2-(p-tolylamino)acetohydrazideor salt thereof to a subject wherein the subject is diagnosed withchronic obstructive pulmonary disease.
 7. The method of claim 6 wherein((E)-N′-(3,5-dibromo-2,4-dihydroxybenzylidene)-2-(p-tolylamino)acetohydrazideor salt thereof is administered in combination with an antibiotic. 8.The method of claim 7 wherein the antibiotic is colistin, clavulanate,aztreonam, ceftazidime, ciprofloxacin, gentamicin, tobramycin, salt orcombination thereof.
 9. The method of claim 6 wherein((E)-N′-(3,5-dibromo-2,4-dihydroxybenzylidene)-2-(p-tolylamino)acetohydrazideor salt thereof is administered in combination with a bronchodilator.10. The method of claim 9 wherein the bronchodilator is salbutamol,albuterol, levosalbutamol, levalbuterol, pirbuterol, epinephrine,ephedrine, terbutaline, salmeterol, clenbuterol, formoterol, bambuterol,indacaterol, theophylline, tiotropium, ipratropium, salt or combinationsthereof.